Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXON ENTERPRISE, INC.AXON · Entity 567 | Director | May 12, 2023 | May 16, 2023 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXON ENTERPRISE, INC.
Report date May 12, 2023 · Filed May 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,135 |
Reported balance
After 2023-05-12 transaction · row 1
1 source rowRow 1 · 2023-05-12 · Grant · Acquired 993 · Balance 11,135 F1: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2022 Stock Incentive Plan. The grant is scheduled to vest on May 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. 2022 Stock Incentive Plan. The grant is scheduled to vest on May 13, 2024.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,295 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 27,295 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 307 | $41.56 | $12,758.92 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 22 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,434 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 400 | $41.55 | $16,620.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 21 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,741 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.55 | $4,154.80 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 20 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,141 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 273 | $41.54 | $11,340.42 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 19 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,241 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 129 | $41.53 | $5,357.37 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 18 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,514 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 818 | $41.52 | $33,963.36 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 17 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,643 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 276 | $41.51 | $11,455.38 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 16 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,461 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 453 | $41.50 | $18,799.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 15 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,737 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.50 | $4,149.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 14 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,190 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.49 | $4,149.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 13 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,290 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $41.49 | $12,445.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 12 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,390 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,900 | $41.48 | $78,812.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 11 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,690 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $41.48 | $12,442.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 10 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,590 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,771 | $41.47 | $73,443.37 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 9 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,890 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 300 | $41.47 | $12,439.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 8 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,661 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 500 | $41.46 | $20,730.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 7 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,961 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.46 | $4,145.80 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 6 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,461 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 53 | $41.45 | $2,196.90 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 5 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,561 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $41.45 | $8,290.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 4 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,614 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.45 | $4,144.50 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 3 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,814 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $41.44 | $4,144.00 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,914 Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 8,580 | $27.24 | $233,719.20 |
DisclosureSEC source: 0001127602-17-018533 · form4.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2014 Filed Jun 29, 2018 22:02 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | SaleCommon Stock | 3,100 | $22.85 | $70,835.00 |
DisclosureSEC source: 0001069183-18-000080 · wf-form4_153030971449397.xml · nonDerivative · entry 2 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,202 F2 · shares: Due to an administrative coding error by the reporting person's broker, the reporting person inadvertently did not report this open market sale transaction on Form 4 in 2014. F3 · balance_after: During 2003 and 2004 the reporting person was granted 20,833 options in connection with the reporting person's service on the registrant's board of directors. Due to an administrative oversight, these options were incorrectly reported on Form 4 as the acquisition of non-derivative securities in Table I at the time of grant, while correctly reported as the acquisition of derivative securities in Table II. Upon exercise of the options by the reporting person in subsequent periods, the acquisitions were correctly reported as the disposition of the derivative securities in Table II and the acquisition of non-derivative securities in Table I. As a result of the incorrect reporting, beneficial ownership for the reporting person has been overstated by 20,833 shares in all Form 4s filed relating to the registrant since 2004 and prior to the date of hereof. Accordingly, the Amount of Securities Beneficially Owned Following Reported Transaction(s) above has been reduced by 20,833 shares. Read SEC document |
| June 07, 2013 Filed Jun 29, 2018 22:02 UTC | AXON ENTERPRISE, INC. AAXN · Entity 567 | GiftCommon Stock | 2,070 | $9.43 | $19,520.10 |
DisclosureSEC source: 0001069183-18-000080 · wf-form4_153030971449397.xml · nonDerivative · entry 1 KROLL MARK W · CIK 0001259254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,135 F1 · shares: The reporting person inadvertently failed to report this disposition by gift on Form 5 for the registrant's 2013 fiscal year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.